WebJul 19, 2024 · Shares in Cytokinetics surged after it reported positive mid-stage results for CK-274, a drug for hypertrophic cardiomyopathy (HCM) that could tread on the toes of Bristol-Myers Squibb's ... WebOct 10, 2024 · While Cytokinetics is pushing forward in ALS, the company’s also developing a drug for heart failure called omecamtiv mecarbil that’s under FDA review. A panel of FDA advisers is set to meet to discuss the drug in mid-December, after which the agency is expected to deliver a decision by February 2024. Filed Under: Clinical Trials
Cytokinetics Muscle Biology Therapies Company
WebApr 6, 2024 · Free-Float. 95,1%. More Financials. Company. Cytokinetics Inc. is a late-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. It is developing small molecule drug candidates specifically … WebMar 31, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential … how do i shrink my task bar at the bottom
STOCK QUOTE Cytokinetics, Inc.
WebFeb 27, 2024 · On Feb. 28, the FDA is set to decide on Cytokinetics ’ omecamtiv mecarbil (OM), a novel, selective cardiac myosin activator being evaluated for heart failure with reduced ejection fraction. The regulatory agency accepted the New Drug Application for OM in February 2024 and initially set a target action date of Nov. 30, 2024. WebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential... WebFeb 4, 2024 · SOUTH SAN FRANCISCO, Calif., Feb. 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) has accepted and filed the... how do i shrink my yoga pants